RedHill Biopharma Ltd.: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

-- Top-line results are expected to be announced in mid-2018
  -- The Phase III study evaluating RHB-104 for Crohn's disease (MAP US study)
     is a randomized, double-blind, placebo-controlled study that is evaluating
     the safety and efficacy of RHB-104 in 331 subjects with moderately to
     severely active Crohn's disease
  -- Worldwide sales of Crohn's disease therapies exceeded $7.6 billion in 2016
  -- A pivotal Phase III study with RHB-104 for Nontuberculous Mycobacteria
     (NTM) infections, with Fast-Track development status, is planned to be
     initiated in H1/2018

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- RedHill
Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the
"Company"), a specialty biopharmaceutical company primarily focused on late
clinical-stage development and commercialization of proprietary drugs for
gastrointestinal and inflammatory diseases and cancer, today announced that the
last patient has been enrolled in the Phase III study with RHB-104 for Crohn's
disease (MAP US study). Top-line results are expected to be announced in
mid-2018. 

The MAP US study is a randomized, double-blind, placebo-controlled first Phase
III study evaluating the safety and efficacy of RHB-104 in subjects with
moderately to severely active Crohn's disease (defined as Crohn's Disease
Active Index (CDAI) between 220 and 450). The primary endpoint of the MAP US
study is disease remission, defined as a reduction in CDAI to less than 150 at
week 26. The study enrolled 331 patients across approximately 150 clinical
sites in the U.S., Canada, Europe, Israel, Australia and New Zealand. 

Two pre-planned independent Data and Safety Monitoring Board (DSMB) meetings
have been held to review data from the MAP US study, in which unanimous
recommendations were given to continue the study without any changes to the
protocol, investigator's brochure, study conduct or informed consent form. At
the first DSMB meeting, held in December 2016, safety data from the study was
reviewed. At the second DSMB meeting, held in July 2017, safety and efficacy
data from the first 222 subjects who had completed week 26 assessments of the
study was reviewed. 

In addition, an open-label extension Phase III study (the MAP US2 study)
continues to evaluate the safety and efficacy of RHB-104 in subjects who remain
with active Crohn's disease (CDAI = 150) after 26 weeks of blinded study
therapy in the ongoing Phase III MAP US study. These subjects have the
opportunity to receive treatment with RHB-104 for a 52-week period in the
open-label MAP US2 extension study. The data collected in the MAP US2 study
will be supplemental to the MAP US study data. The MAP US2 study's primary
endpoint is disease remission at week 16, defined as CDAI of less than 150. The
MAP US2 study is planned to enroll approximately 50-70 subjects in the U.S.,
Canada, Europe, Israel and New Zealand. Additional open-label studies with
RHB-104 for Crohn's disease are being planned to generate further supportive
clinical data for potential future marketing applications. 

Additional clinical studies are likely to be required to support a U.S. New
Drug Application (NDA) for RHB-104. If the MAP US study results are positive,
RedHill will meet with the U.S. Food and Drug Administration (FDA) and key
opinion leaders to present the data package and discuss the preferred
development path. 

The worldwide sales of Crohn's disease therapies exceeded $7.6 billion in 20161.

In addition to the ongoing Phase III studies with RHB-104 for Crohn's disease,
RedHill plans, subject to regulatory approvals, to initiate a pivotal Phase III
study with RHB-104 for the treatment of nontuberculous mycobacteria (NTM)
infections in the U.S. in the first half of 2018. RHB-104 was granted Qualified
Infectious Disease Product (QIDP) status by the FDA for the treatment of NTM
infections. QIDP designation allows for Fast-Track development status, Priority
Review of an NDA, if filed, and an additional five years of U.S. market
exclusivity on top of the standard exclusivity period or Orphan Designation
exclusivity period, as applicable, for a total U.S. market exclusivity of 8-12
years. 

The clinical studies with RHB-104 are registered on www.ClinicalTrials.gov, a
web-based service of the U.S. National Institute of Health, which provides
access to information on publicly and privately-supported clinical studies. 

About RHB-104:
Currently in a first Phase III study for the treatment of Crohn's disease (the
MAP US study), with top-line results expected in mid-2018, RHB-104 is a
proprietary, orally-administered, potentially ground-breaking oral antibiotic
combination therapy, with potent intracellular, antimycobacterial and
anti-inflammatory properties. RHB-104 is based on increasing evidence
supporting the hypothesis that Crohn's disease is related to Mycobacterium
avium subspecies paratuberculosis (MAP) infection in susceptible patients. The
development of RHB-104 is consistent with the growing awareness of the
possibility that a bacterially-induced dysregulated immune system may
contribute to the pathogenesis of various autoimmune diseases of unknown
etiology. Clinical trials conducted with earlier formulations of RHB-104
include an Australian Phase III study conducted by Pharmacia/Pfizer. RedHill
has conducted several supportive studies with the current formulation of
RHB-104 and a long-term population pharmacokinetic (pop-PK) study is ongoing as
part of the Phase III MAP US study. Additionally, an open-label extension Phase
III study (the MAP US2 study) is ongoing to assess the safety and efficacy of
RHB-104 in subjects who have completed week 26 assessments in the ongoing Phase
III MAP US study and remain with active Crohn's disease (CDAI = 150) at week
26. RHB-104 is covered by several issued and pending patents. RHB-104 was
granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA
for the treatment of nontuberculous mycobacteria (NTM) infections, providing a
Fast-Track development pathway, as well as NDA Priority Review and an
additional five years of U.S. market exclusivity, if approved. A pivotal Phase
III study with RHB-104 for NTM infections is planned to be initiated. RedHill
also completed a Phase IIa, proof-of-concept clinical study, evaluating RHB-104
as an add-on therapy to interferon beta-1a in subjects treated for
relapsing-remitting multiple sclerosis (the CEASE MS study), supporting
additional studies. 

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a
specialty biopharmaceutical company, primarily focused on the development and
commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for the treatment of gastrointestinal and inflammatory
diseases and cancer. RedHill promotes three gastrointestinal products in the
U.S., and its clinical-stage pipeline includes treatments for gastrointestinal
indications, pancreatic cancer and acute migraines: Donnatal - a prescription
oral adjunctive drug used in the treatment of IBS and acute enterocolitis;
Esomeprazole Strontium Delayed-Release Capsules 49.3 mg - a prescription proton
pump inhibitor indicated for adults for the treatment of gastroesophageal
reflux disease (GERD) and other gastrointestinal conditions; and EnteraGam - a
medical food intended for the dietary management, under medical supervision, of
chronic diarrhea and loose stools. RedHill's clinical-stage pipeline includes:
(i) TALICIA (RHB-105) - an oral combination therapy for the treatment of
Helicobacter pylori infection with successful results from a first Phase III
study and an ongoing confirmatory Phase III study; (ii) RHB-104 - an oral
combination therapy for the treatment of Crohn's disease with an ongoing first
Phase III study, a completed proof-of-concept Phase IIa study for multiple
sclerosis, and a planned pivotal Phase III study for nontuberculous
mycobacteria (NTM) infections; (iii) BEKINDA (RHB-102) - a once-daily oral
pill formulation of ondansetron with successful top-line results from a Phase
III study in acute gastroenteritis and gastritis and successful top-line
results from a Phase II study in IBS-D; (iv) RHB-106 -an encapsulated bowel
preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA (ABC294640) -a
Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor
targeting multiple oncology, inflammatory and gastrointestinal indications;
(vi) MESUPRON - a Phase II-stage first-in-class, orally-administered protease
inhibitor, targeting pancreatic cancer and inflammatory gastrointestinal
diseases and (vii) RIZAPORT (RHB-103) - an oral thin-film formulation of
rizatriptan for acute migraines, with a U.S. NDA resubmitted to the FDA and
marketing authorization received in two EU member states under the European
Decentralized Procedure (DCP). 

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements may be
preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential" or similar words. Forward-looking statements are based on
certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and cannot be
predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks
and uncertainties include, without limitation, risks and uncertainties
associated with (i) the initiation, timing, progress and results of the
Company's research, manufacturing, preclinical studies, clinical trials, and
other therapeutic candidate development efforts; (ii) the Company's ability to
advance its therapeutic candidates into clinical trials or to successfully
complete its preclinical studies or clinical trials; (iii) the extent and
number of additional studies that the Company may be required to conduct and
the Company's receipt of regulatory approvals for its therapeutic candidates,
and the timing of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market acceptance
of the Company's therapeutic candidates; (v) the Company's ability to
successfully market Donnatal and EnteraGam; (vi) the Company's ability to
establish and maintain corporate collaborations; (vii) the Company's ability to
acquire products approved for marketing in the U.S. that achieve commercial
success and build its own marketing and commercialization capabilities; (viii)
the interpretation of the properties and characteristics of the Company's
therapeutic candidates and the results obtained with its therapeutic candidates
in research, preclinical studies or clinical trials; (ix) the implementation of
the Company's business model, strategic plans for its business and therapeutic
candidates; (x) the scope of protection the Company is able to establish and
maintain for intellectual property rights covering its therapeutic candidates
and its ability to operate its business without infringing the intellectual
property rights of others; (xi) parties from whom the Company licenses its
intellectual property defaulting in their obligations to the Company; (xii)
estimates of the Company's expenses, future revenues capital requirements and
needs for additional financing; (xiii) the effect of patients suffering adverse
experiences using investigative drugs under the Company's Expanded Access
Program; and (xiv) competition from other companies and technologies within the
Company's industry. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set
forth in the Company's filings with the Securities and Exchange Commission
(SEC), including the Company's Annual Report on Form 20-F filed with the SEC on
February 23, 2017. All forward-looking statements included in this press
release are made only as of the date of this press release. The Company assumes
no obligation to update any written or oral forward-looking statement, whether
as a result of new information, future events or otherwise, unless required by
law. 

Company contact:                            IR contact (U.S.):   
Adi Frish                                   Marcy Nanus          
Senior VP Business Development & Licensing  Senior Vice President
RedHill Biopharma                           The Trout Group      
[phone]                            [phone]      
[e-mail]                          [e-mail]

__________________

1 EvaluatePharma, estimated market for diagnosis and drug treatment of Crohn's
disease, January 2017.